Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20
10/15/18
10/15
10:20
10/15/18
10:20

Roche breast cancer data could pressure Puma shares, says RBC Capital

RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

RHHBY

Roche

$0.00

(0.00%)

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

PBYI Puma Biotechnology
$42.19

-0.5 (-1.17%)

09/17/18
GSCO
09/17/18
INITIATION
Target $42
GSCO
Sell
Puma Biotechnology initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Paul Choi started Puma Biotechnology with a Sell rating and $42 price target. The analyst sees see 11% downside in the shares versus 20% upside on average for his coverage universe. While the company's Nerlynx launch in the extended adjuvant setting in HER2+ breast cancer has gone well to date, channel checks and analysis suggest that consensus estimates are overly optimistic with respect to patient adds in this setting, Choi tells investors in a research note. The analyst initiated coverage of the smid-cap biotech sector with a Neutral coverage view. He views sector fundamentals as healthy but says high valuations temper his enthusiasm.
09/17/18
GUGG
09/17/18
INITIATION
Target $85
GUGG
Buy
Puma Biotechnology initiated with a Buy at Guggenheim
Target $85.
09/18/18
09/18/18
NO CHANGE
Target $151

Buy
Physician survey supports Puma's Nerlynx hitting $1B in sales, says Citi
Citi analyst Yigal Nochomovitz says his 100-physician survey of U.S. oncologists supports his "long-standing bull thesis" that Puma Biotechnology's Nerlynx is positioned to be a billion-dollar drug. Continued fundamental upside to the launch should limit investor concerns around a "stalled" launch that has been pressuring the stock, Nochomovitz tells investors in a research note. The survey indicates that one-in-four adjuvant Herceptin patients are expected to receive Nerlynx. This provides "substantive validation" that 20%-25% of Herceptin completers are high-risk and thus likely Nerlynx patients, Nochomovitz contends. The analyst lowered his price target for Puma shares to $151 from $164 and keeps a Buy rating on the name.
10/01/18
CANT
10/01/18
INITIATION
Target $75
CANT
Overweight
Puma Biotechnology initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Puma Biotechnology with an Overweight rating and $75 price target.
RHHBY Roche
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.

TODAY'S FREE FLY STORIES

D

Dominion

$74.40

0.82 (1.11%)

, SCG

Scana

$43.70

0.75 (1.75%)

17:18
11/19/18
11/19
17:18
11/19/18
17:18
Hot Stocks
NCUC approves Dominion-SCANA combination »

The proposed combination…

D

Dominion

$74.40

0.82 (1.11%)

SCG

Scana

$43.70

0.75 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

17:17
11/19/18
11/19
17:17
11/19/18
17:17
Hot Stocks
Northrop Grumman awarded $489.92M Air Force contract »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

CLDR

Cloudera

$11.23

-0.915 (-7.53%)

, HDP

Hortonworks

$14.52

-1.23 (-7.81%)

17:17
11/19/18
11/19
17:17
11/19/18
17:17
Hot Stocks
Hortonworks, Cloudera terminate waiting period for proposed merger »

Cloudera (CLDR) and…

CLDR

Cloudera

$11.23

-0.915 (-7.53%)

HDP

Hortonworks

$14.52

-1.23 (-7.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

PLSE

Pulse Biosciences

$13.35

0.545 (4.26%)

17:16
11/19/18
11/19
17:16
11/19/18
17:16
Syndicate
Pulse Biosciences commences $45M rights offering »

Pulse Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$69.46

-1.38 (-1.95%)

17:15
11/19/18
11/19
17:15
11/19/18
17:15
Hot Stocks
Xylem signs MOU with Ethiopia government on water security »

Xylem has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

, SAIC

SAIC

$68.30

-2.18 (-3.09%)

17:12
11/19/18
11/19
17:12
11/19/18
17:12
Hot Stocks
Northrop Grumman, SAIC and others awarded $577.47M in Navy contracts »

Northrop Grumman (NOC),…

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

SAIC

SAIC

$68.30

-2.18 (-3.09%)

GD

General Dynamics

$179.25

-3.86 (-2.11%)

BAH

Booz Allen

$51.90

-0.79 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 06

    Dec

  • 11

    Jan

IR

Ingersoll-Rand

$103.29

-1.045 (-1.00%)

17:12
11/19/18
11/19
17:12
11/19/18
17:12
Initiation
Ingersoll-Rand initiated  »

Ingersoll-Rand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

CARB

Carbonite

$25.89

-1.78 (-6.43%)

17:11
11/19/18
11/19
17:11
11/19/18
17:11
Hot Stocks
Carbonite announces $50M stock repurchase program »

Carbonite announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PES

Pioneer Energy

$2.75

-0.01 (-0.36%)

17:11
11/19/18
11/19
17:11
11/19/18
17:11
Initiation
Pioneer Energy initiated  »

Pioneer Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

RNGR

Ranger Energy

$7.62

-0.53 (-6.50%)

17:10
11/19/18
11/19
17:10
11/19/18
17:10
Initiation
Ranger Energy initiated  »

Ranger Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SERV

ServiceMaster

$41.84

-0.58 (-1.37%)

17:09
11/19/18
11/19
17:09
11/19/18
17:09
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

17:06
11/19/18
11/19
17:06
11/19/18
17:06
Earnings
Kulicke & Soffa sees Q1 revenue $150M-$160M, consensus $191.06M »

Looking forward, Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

17:04
11/19/18
11/19
17:04
11/19/18
17:04
Earnings
Kulicke & Soffa reports Q4 EPS 45c versus 62c in Q4 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

ENTG

Entegris

$26.20

-1.07 (-3.92%)

17:04
11/19/18
11/19
17:04
11/19/18
17:04
Hot Stocks
Entegris announces additional $250M share repurchase authorization »

Entegris announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SCI

Service Corp.

$44.69

-0.185 (-0.41%)

17:03
11/19/18
11/19
17:03
11/19/18
17:03
Hot Stocks
Service Corp. exec Sangalis sells 23,617 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$10.92

-0.63 (-5.45%)

17:02
11/19/18
11/19
17:02
11/19/18
17:02
Initiation
Emerald Expositions Events initiated  »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$179.63

-3.47 (-1.90%)

16:58
11/19/18
11/19
16:58
11/19/18
16:58
Initiation
Cintas initiated  »

Cintas initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:52
11/19/18
11/19
16:52
11/19/18
16:52
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

, AMZN

Amazon.com

$1,511.67

-81.92 (-5.14%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Initiation
ADT Inc., Amazon.com initiated  »

ADT Inc. initiated with…

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

AMZN

Amazon.com

$1,511.67

-81.92 (-5.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

NUAN

Nuance

$16.27

-0.61 (-3.61%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Nuance trades higher after quarterly report, plans to spin off Nuance Auto »

Shares of Nuance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Conference/Events
Bio Blast Pharma to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.56

-1.56 (-8.16%)

16:48
11/19/18
11/19
16:48
11/19/18
16:48
Hot Stocks
Pure Storage up 6.4% after Q3 results beat estimates, FY19 guidance raised »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

ORPN

Bio Blast Pharma

$1.19

-0.02 (-1.65%)

16:45
11/19/18
11/19
16:45
11/19/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Bio Blast Pharma »

Bio Blast Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADT

ADT Inc.

$7.68

-0.39 (-4.83%)

16:43
11/19/18
11/19
16:43
11/19/18
16:43
Initiation
ADT Inc. initiated  »

ADT Inc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:42
11/19/18
11/19
16:42
11/19/18
16:42
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.